Q-omics provides the consensus-scored DMWD profile across patient tissues and cancer cell-line models. DMWD expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, DMWD is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, DMWD RNA expression shows 19,628 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where DMWD shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DMWD — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DMWD survival associations across molecular data types. DMWD RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DMWD RNA expression–survival associations across cancer types. High DMWD expression shows unfavorable associations in ACC, LGG, COAD, LIHC, OV and LUAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for DMWD RNA expression.
This table summarizes DMWD tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for DMWD. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DMWD shows lower tumor expression in UCEC and higher tumor expression in HNSC, COAD, LIHC, CHOL and LUSC. The HNSC box plot shows higher DMWD RNA expression in tumor versus normal tissue (log2 FC = +0.933, t-test p < 0.001).
This table shows molecular features associated with DMWD in patient tissues and cancer cell lines. In patient samples, DMWD shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, DMWD RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
